Clinical trials: HV

Healthy

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

• Completed
• Age: 18 to 80 years
• Phase 2
• Results posted

Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment.

Trial name

NCT00075335

Testing

AMD3100 (Mozobil plerixafor)

Where

United States

Volunteers

8 people, healthy volunteers welcome

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)